Alnylam Pharmaceuticals Inc ALNY
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALNY is a good fit for your portfolio.
News
-
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
-
Alnylam's stock surges as heart drug vies with a Pfizer blockbuster
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
-
Alnylam Issues 2023 Corporate Responsibility Report
-
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
-
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
-
Alnylam Ending Onpattro ATTR-CM Pursuit After FDA Rejection
-
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter
Trading Information
- Previous Close Price
- $237.88
- Day Range
- $233.42–240.31
- 52-Week Range
- $141.98–263.73
- Bid/Ask
- $234.00 / $234.81
- Market Cap
- $29.71 Bil
- Volume/Avg
- 524,476 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,100
- Website
- https://www.alnylam.com
Competitors
Valuation
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.09 |
Price/Book Value | — | 25.31 | 2.86 |
Price/Sales | 14.70 | 9.53 | 4.12 |
Price/Cash Flow | 137.94 | — | 19.82 |
Price/Earnings
ALNY
IONS
INCY
Financial Strength
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.86 | 6.75 | 3.29 |
Current Ratio | 3.17 | 7.37 | 3.47 |
Interest Coverage | −2.38 | −3.53 | 333.13 |
Quick Ratio
ALNY
IONS
INCY
Profitability
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | −2.47% | −9.42% | 13.25% |
Return on Equity (Normalized) | — | −71.60% | 17.32% |
Return on Invested Capital (Normalized) | −7.00% | −11.55% | 14.51% |
Return on Assets
ALNY
IONS
INCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Zpdkmdrjmp | Cldnj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jrqvyzv | Xynfk | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dlwbskp | Jgmcv | $118.7 Bil | |||
| Moderna Inc
MRNA
| Ydlsxrzp | Wbspc | $46.8 Bil | |||
| argenx SE ADR
ARGX
| Zwssznph | Mptd | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Crgnpjt | Jdt | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qhpgwvj | Mzbvlz | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ssmhvvvx | Yjfv | $15.0 Bil | |||
| Incyte Corp
INCY
| Dtvbcmn | Xzxqvn | $13.5 Bil |